Last reviewed · How we verify
NCT03417063
Intracranial Artery Stenosis Magnetic Resonance Imaging: Aetiology and Progression
trial in Ischemic Stroke in 300 participants. Status unknown.
25 March 2021
Quick facts
| Lead sponsor | Tsinghua University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 14 October 2017 |
| Primary completion | 25 March 2021 |
| Estimated completion | 25 March 2022 |
| Sites | 1 location across China |
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Transient Ischemic Attack — all drugs for Transient Ischemic Attack →
- Intracranial Artery Stenosis — all drugs for Intracranial Artery Stenosis →
Sponsor
Tsinghua University
Who can join
Adults 18 to 80, any sex, with Ischemic Stroke or Transient Ischemic Attack. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stroke has become the leading cause of death in China. It has been shown that intracranial artery stenosis (ICAS) plays a key role in Chinese stroke patients. Although most of stenotic diseases in intracranial arteries are atherosclerotic, a substantial number of other vascular diseases, such as dissection, arteritis, moyamoya disease, and reversible cerebral vasoconstriction syndrome (RCVS), can also lead to intracranial artery luminal narrowing. It is challenging to differentiate the etiologies of ICAS relying on measuring luminal narrowing by angiographical approaches. In addition, the progression of intracranial atherosclerotic disease (ICAD) has been demonstrated to be highly associated with the risk of ischemic cerebrovascular events. However, the influence factors for ICAD progression remains unclear. High-resolution magnetic resonance imaging (HR-MRI) has been widely used to assess ICAS diseases. The different etiologies of ICAS are differentiable by MR-MRI according to the features of location, shape, signal pattern, remodeling, and contrast enhancement. Investigators have proved that HR-MRI is a reproducible technique that may be reliably utilized to monitor the changes of ICAD during natural follow-up or medical treatment. The ICASMAP (Intracranial Artery Stenosis MR Imaging: Aetiology and Progression) is a prospective, cross-sectional, observational, and multicenter study. The objectives of ICASMAP are to determine: 1) the spectrum of etiology of ICAS in stroke patients; and 2) the influence factors for progression of ICAD. A total of 300 patients with symptomatic stenotic disease in intracranial arteries (stenosis range: 30%-99%) will be recruited within two weeks after symptom onset from 18 different hospitals across Beijing-Tianjin-Hebei region in China within 1 year. All the patients will undergo HR-MRI for intracranial arteries at baseline, one-year, and two-years. The clinical risk factors will be collected and blood draw will be conducted. The ICASMAP study may help to improve the precise diagnosis and intervention of ICAS and stroke prevention.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Intracranial artery stenosis magnetic resonance imaging aetiology and progression study: Rationale and design.
Han Y, Qiao H, Chen S, Jing J, et al · · 2018 · cited 9× · PMID 30456898 · DOI 10.1002/brb3.1154 -
Risk Factors for Asymptomatic and Symptomatic Intracranial Atherosclerosis Determined by Magnetic Resonance Vessel Wall Imaging in Chinese Population: A Case-Control Study.
Han Y, Zhang R, Yang D, Li D, et al · · 2022 · cited 3× · PMID 35058694 · DOI 10.2147/tcrm.s335401
Verify or expand the search:
- PubMed search for NCT03417063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Tsinghua University trials
Trials by the same sponsor.
- NCT07171086 — AI-POCUS for Maternal and Neonatal Health in Ethiopia · Phase 4 · not yet recruiting
- NCT06980467 — Evaluation of AI-Generated Clinical Advice by Physicians · NA · not yet recruiting
- NCT06962423 — AI-driven Automated Biomedical Research · NA · not yet recruiting
- NCT06923410 — Clinical Intelligent Management System - Multilingual Exploration · NA · recruiting
- NCT06893068 — Clinical Intelligent Management System Pragmatic RCT · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03417063 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tsinghua University
- Last refreshed: 31 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03417063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing